InVivo Therapeutics Holdings Corp. (NVIV) News

InVivo Therapeutics Holdings Corp. (NVIV): $4.29

0.04 (+0.94%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NVIV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 507

in industry

Filter NVIV News Items

NVIV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NVIV News From Around the Web

Below are the latest news stories about INVIVO THERAPEUTICS HOLDINGS CORP that investors may wish to consider to help them evaluate NVIV as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Pre-market stock movers are the hot topic this morning as we cover all the latest news sending shares higher and lower on Monday!

William White on InvestorPlace | August 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Good morning!

William White on InvestorPlace | August 5, 2022

What Is Going on With InVivo Therapeutics (NVIV) Stock Today?

InVivo Therapeutics (NVIV) stock is rocketing higher on Thursday despite a lack of news concerning the biotechnology company.

William White on InvestorPlace | August 4, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | August 4, 2022

InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel

CAMBRIDGE, Mass., July 13, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company’s legal and intellectual property functions, and provide strategic guidance to the company’s Board of Directors and executive management team

Yahoo | July 13, 2022

InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

CAMBRIDGE, Mass., June 08, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced the publication of a peer-reviewed manuscript in Neurosurgery describing the previously disclosed 12- and 24-month data from the Company's single-arm INSPIRE 1.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). The publication is titled "Acute Implantation of a Bioresorbable Polymer

Yahoo | June 8, 2022

InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study

CAMBRIDGE, Mass., June 02, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has completed enrollment in the INSPIRE 2.0 Study for patients with acute spinal cord injury. The 20-patient study is a randomized, controlled trial featuring 10 subjects in each study arm, designed to enhance the existing clinical evidence for the Neuro-Spinal Scaffo

Yahoo | June 2, 2022

Why Are InVivo Therapeutics Shares Trading Lower During Premarket Monday?

InVivo Therapeutics Holdings Corp (NASDAQ: NVIV) has announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focusing on treating spinal cord injuries. The company anticipates the reverse stock split will become effective and start trading on a post-split basis on April 27. Every 25 shares of InVivo Therapeutics common stock will be combin

Yahoo | April 18, 2022

InVivo Therapeutics Announces Reverse Stock Split

CAMBRIDGE, Mass., April 14, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 26, 2022, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the company's existing trading symbol, "NVIV," at the market open on April 27, 2022. T

Yahoo | April 14, 2022

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., January 06, 2022--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming virtual H.C. Wainwright BioConnect Conference, which runs from January 10 – 13, 2022. Dr. Toselli’s presentation will provide an overview of the company and will also highlight

Yahoo | January 6, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4995 seconds.